Thalomid: profile and news
APS: For Migraine and Cluster Headaches, Most Anything Is Worth a ... May 15, 2006
Another older drug being used in headache relief is Thalomid (thalidomide), the teratogenic drug that was off the market for decades but is making a comeback ... - MedPage Today,
Drug costs outrage pharmacist May 11, 2006
But how do drug companies explain the high cost of really old drugs like Thalomid, which costs thousands of dollars for a month's supply? ... - Therapeutics Daily (subscription) (press release),
Drug plan battle May 6, 2006
As a result, her two-month supply of Thalomid shot up from $40 to a whopping $1,300. "If I can't get it, I guess I'm here until the Lord takes me out. ... - Joliet Herald News,
Celgene Shares Get a Lift Apr 27, 2006
Cramer's Take) first-quarter revenue jumped nearly 62%, and earnings beat analysts' targets thanks to strong showings from its key drugs Revlimid and Thalomid. ... - TheStreet.com
Celgene Might Be Trouble for Millennium Apr 26, 2006
...from the Food and Drug Administration, Duncan believes Revlimid will be a significant threat to Velcade and probably cannibalize sales of Thalomid, a Celgene ... - TheStreet.com
Cancer drug sales help push Celgene's strong quarter Apr 28, 2006
Revenues jumped nearly 62 percent to $181.8 million on strong sales of both Revlimid and Thalomid, drugs used to treat cancer. Sales ... - NorthJersey.com,
Drug Plan Gone Bad Apr 21, 2006
..." I don't guess there's anything I can do about it.". Lindley has taken Thalomid, a drug used to treat bone cancer, for three years. ... - KAIT,
A ‘doughnut hole’ you could drive an ambulance through Apr 27, 2006
...“I’m in the hole all right,� Mildred Lindley told the Associated Press. Her two-month supply of Thalomid shot up to $1,300 from $40. ... - Boston Herald,
Celgene reports 62% jump in revenue Apr 27, 2006
Sales of the company's lead drug Thalomid, a treatment for leprosy based on the compound thalidomide, rose 21% to $107.2 million. ... - MarketWatch
Celgene's 1Q Impresses, Shares Up Apr 27, 2006
Quarterly revenue surged 61.7 percent to $181.8 million from $112.4 million last year, driven by higher sales of anticancer drugs Thalomid and Revlimid. ... - MSN Money
Celgene Q1 Adj. EPS Tops Consensus; Revenues Jump 62% - Update Apr 27, 2006
The higher revenues were attributed to strong THALOMID net sales of $107.2 million, an increase of 21.3% year-over-year, and REVLIMID net sales of $32.4 million ... - Trading Markets,
Medicare's 'doughnut hole' Apr 28, 2006
...bone marrow cancer in remission. As a result, her two-month supply of Thalomid shot up from $40 to a whopping $1,300. "If I can't ... - Kentucky.com,
Celgene Corporation Reports Record Revenue and Operating Profits Apr 27, 2006
Product Sales Drive Record First Quarter Revenue and Profits: - Strong REVLIMID(R) Launch Achieved $32.4 Million in Net Product Sales - Record THALOMID(R) Net ... - PR Newswire (press release),
Medicare's 'doughnut hole' Apr 28, 2006
...bone marrow cancer in remission. As a result, her two-month supply of Thalomid shot up from $40 to a whopping $1,300 . "If I can't ... - Therapeutics Daily (subscription) (press release),
Celgene Corporation Reports Record Revenue and Operating Profits Apr 27, 2006
...was a record $181.8 million for the quarter ended March 31, 2006, an increase of 61.8% over the same period in 2005 driven by strong THALOMID® net sales of ... - Yahoo! News (press release)
Celgene upgraded to "outperform" - update May 1, 2006
Bear Stearns also expresses its optimism regarding the presentations by the company on Thalomid/Revlimid at the forthcoming ASCO meeting in June. - newratings.com
Celgene results top estimates; shares jump Apr 27, 2006
Estimates. Sales of Thalomid, approved for leprosy but which is mostly used to treat multiple myeloma, rose 21 percent to $107.2 million. ... - Reuters
UPDATE 1-Celgene posts lower 1st-quarter profit, revs jump Apr 27, 2006
The revenue jump was driven by a 21 percent rise to $107.2 million for sales of Celgene's flagship drug Thalomid, a drug approved for leprosy but which derives ... - Reuters
US stocks rise, boosted by Bernanke rate remarks Apr 28, 2006
...shoot up 12.8% to $42.45 after the biotech's earnings handily topped analyst estimates, with revenue up more than 60% on strong sales of Thalomid, a treatment ... - Middle East North Africa Financial Network,
